Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. - Wikidata - awgldk - TriplyDB

Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.

Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.

http://www.wikidata.org/entity/Q36785790

about

Management of Mycoplasma genitalium infections - can we hit a moving target?Antibiotics in the clinical pipeline at the end of 2015.Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid.In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States The good, the bad and the tasty: The many roles of mushrooms.Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance.New antibiotics for bad bugs: where are we?New antibacterial agents: patent applications published in 2011.Fungal natural products in research and development.Natural product and natural product derived drugs in clinical trials.Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium.Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively-drug resistant Neisseria gonorrhoeae.A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism.Mycoplasma genitalium infections: current treatment options and resistance issues.Biosynthetic Machinery of Diterpene Pleuromutilin Isolated from Basidiomycete Fungi.In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens.

P2860

Q26796722-863B2D6B-6006-4E87-B8E2-D87F57550283 Q30249262-6FAB4704-A2C2-4713-91FA-6957360C2531 Q34497915-B9A6239D-B6A6-4275-B766-13931F299C69 Q34508161-7A9E5B2E-61DF-4607-8CB7-DC747EF70489 Q34525879-A0EEF2AD-F2F6-48CD-856B-48F803FBA40E Q37570744-4E125916-D307-4B51-A927-FFC2FBC12E87 Q37835585-D280F8C2-295E-4189-9BDB-46FE8246BD07 Q38132217-A4511729-6491-414E-BC08-5D951E9CC616 Q38172657-95E8C706-1B0D-43E2-ACF0-BF9F9BE9DA19 Q38239799-67DA0AB5-A555-4D04-AEA0-07AF29F25318 Q38247457-267ECC3E-01FF-4688-9285-B845D98EBD4B Q38772340-A2A8F095-68DF-4D01-A0EA-C3C3C046DE41 Q39362169-9E088F57-3D12-4453-A552-002EE908C6D5 Q40052692-2520FDD8-472D-433D-94E6-D90819A2F22F Q41872353-3C0A6D8F-C9DF-4921-9331-1848C27AA7C8 Q42355223-C8C86063-6AA1-43A2-B844-4D90E87C9DB5 Q47780684-D2D666FC-DB87-427C-9200-867F7979A227 Q52659745-976F43CE-86FC-466D-A437-16DAB99D15BC

P2860

Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.

http://www.wikidata.org/entity/Q36785790

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Phase II clinical study of BC- ...... and skin structure infections.

@en

type

label

Phase II clinical study of BC- ...... and skin structure infections.

@en

prefLabel

Phase II clinical study of BC- ...... and skin structure infections.

@en

P1433

Q36785790-96318B94-2BAC-4EDF-BC6D-1B1FB04FBB66

P1476

Q36785790-41E92F3A-60E5-46B4-A6FB-BD73FA13A9B5

P2093

Q36785790-16131F7A-57C1-464B-9A1C-3CB03D060675

Q36785790-16894B1B-E576-4220-A197-D97987BA3BDA

Q36785790-2D7AC643-F665-446A-BF71-F27819B22014

Q36785790-6D20D03B-B226-4E55-BCE6-1F71811A8B81

Q36785790-774A9A36-FA8E-45FF-AF9B-AE878EB39359

Q36785790-BD244423-C999-4A9C-96A0-0244B399ED97

Q36785790-FA40BC20-E983-4A4E-BAED-096B97CF56E7

P2860

Q36785790-0A832AE6-8E02-4ED7-9549-E5F9BEA76191

Q36785790-126AB480-D0B9-43B1-B0E0-AF85C5AB9BC4

Q36785790-29847BBA-4768-4B91-B8BA-72B6BCAB8E03

Q36785790-3C2771E1-34D3-4D1C-821B-12986A2312FB

Q36785790-7345CAA7-236B-4F06-B7D2-AB80E8EB274F

Q36785790-8C04DB3A-A54A-4F8A-826B-38AF137F2BB3

Q36785790-B25A7E50-FD9F-4CE6-963B-82913264482A

Q36785790-BAFB1A7A-C990-452D-A3FD-795B72570AD8

Q36785790-BE139A70-A2C8-499C-9EE0-9A332D2891C9

Q36785790-BE1A90E6-C334-44A9-8974-0BCE5CF684C1

P304

Q36785790-79E32EBF-CB28-472F-AF29-9C68F479CF23

P31

Q36785790-1BEA43B2-CC27-430C-AC87-96C708890720

P356

Q36785790-A4949555-8D40-49F4-8A3B-B63DA2C5BFEB

P407

Q36785790-BA73D059-F55C-4FD1-9B16-0E92C4A08DD2

P433

Q36785790-2B89CB2B-DFF0-4FA9-A088-E778C2D6257A

P478

Q36785790-AE1A31C9-D720-46FD-85C3-59268D7670EC

P577

Q36785790-E6891B3E-B750-452E-91DC-55F11E5B7AB6

P5875

Q36785790-855FDE6B-B512-4B9E-8DB2-2D269BE7F42A

P698

Q36785790-F28CA8A1-8DD6-4BE3-809C-20D09C0BC094

P932

Q36785790-6FC20BAC-CB9A-40E2-894B-6640460EF987

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Phase II clinical study of BC- ...... and skin structure infections.

@en

P2093

C Lell

http://www.w3.org/2001/XMLSchema#string

F Obermayr

http://www.w3.org/2001/XMLSchema#string

G H Talbot

http://www.w3.org/2001/XMLSchema#string

K J Tack

http://www.w3.org/2001/XMLSchema#string

R Novak

http://www.w3.org/2001/XMLSchema#string

W T Prince

http://www.w3.org/2001/XMLSchema#string

Z Ivezic-Schoenfeld

http://www.w3.org/2001/XMLSchema#string

P2860

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

The pleuromutilin antibiotics: a new class for human use.

Practice guidelines for the diagnosis and management of skin and soft-tissue infections.

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.

Staphylococcus aureus with reduced susceptibility to vancomycin.

Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials.

P304

2087-2094

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02106-12

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235669364

http://www.w3.org/2001/XMLSchema#string

P698

23422913

http://www.w3.org/2001/XMLSchema#string

P932

3632892

http://www.w3.org/2001/XMLSchema#string